Marc Hilmi

13PUBLICATIONS
82CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Mar 27, 2026
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.

Wungki Park, Shigeaki Umeda, Marc Hilmi

|Mar 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.

Wungki Park, Catherine A O'Connor, Joanne F Chou

|Feb 09, 2026
Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression.

Jérémy Nigri, Wenjun Lan, Melanie L Fung

|Sep 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Wungki Park, Catherine O'Connor, Joanne Chou

|Feb 12, 2025
Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach.

Marc Hilmi, Flore Delecourt, Jérôme Raffenne

|Oct 22, 2022
Evaluation of supportive care needs, sexuality and quality of life in phase 1 trials: a prospective monocentric study.

Marc Hilmi, Natacha Naoun, Alice Boilève

Pageof 3

Frequent Collaborators

4 joint publications

Christine Iacobuzio-Donahue

4 joint publications

Wungki Park

3 joint publications

Olca Basturk

3 joint publications

Chaitanya Bandlamudi